Dmitry Klokol
Stellar Biomolecular Research, Frankfurt am Main, Germany.
Title: APPLICATION OF PRECURSOR STEM CELLS AND TARGETED ORGAN-SPECIFIC PEPTIDE THERAPY FOR KIDNEY REGENERATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE
Biography
Biography: Dmitry Klokol
Abstract
Chronic kidney disease (CKD) is characterized by progressive deterioration of renal function due to loss of functioning nephrons. In spite of available treatments CKD is still considered as irreversible, gradually worsening condition that ultimately results in end-stage renal failure (ESRF).
Such situation urges to seek for new advanced therapeutic modalities that are able to restore renal function or at least substantially slow down the progression of CKD. Recent research and studies has shown that the most promising opportunity to restore nephron functionality is stem cell therapy. Due to morphological complexity of the kidney’s ultrastructure the available options of autologous stem cell therapy has proven its failure to restore the anatomy and functionality of nephron. On the other hand embryonic and induced pluripotent stem cells have multiple unsolved safety issues. Latest scientific developments demonstrate that fetal precursor stem cells transplantation is the safest and most reliable method of renal cellular pool replacement in patients with CKD.
In our study we present data on efficacy of combination of precursor stem cells (FCTI) and targeted organ-specific peptides (SBI, MF+, Germany) in patients with CKD. Results of stem cell implantation were evaluated 6 months and 1 year after the procedure. Certain improvements of parameters of renal function test and downstaging of CKD, depending on the stage of the disease, were noted.
There were no adverse reactions observed in treated patients. Precursor stem cells and organ-specific peptides (SBI, MF+, Germany) in management of CKD ise a promising therapeutic modality and requires further detailed analysis and continued clinical trials.